

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761404Orig2s000

OTHER ACTION LETTERS



BLA 761404/Original 2

PROVISIONAL DETERMINATION

Celltrion, Inc.
Attention: Ally Danta
Senior Associate, Regulatory, Parexel International
2520 Meridian Parkway, Suite 100
Durham, NC 27713

Dear Ally Danta:

Please refer to your biologics license application (BLA) dated and received November 30, 2023, and your amendments, submitted under section 351(k) of the Public Health Service (PHS) Act for Stoboclo (denosumab-bmwo) injection and Osenvelt (denosumab-bmwo) injection.

We acknowledge receipt of your major amendment dated November 5, 2024, which extended the goal date by three months.

This BLA seeks licensure of:

- Stoboclo (denosumab-bmwo) injection, 60 mg/mL in a single-dose prefilled syringe (PFS) for subcutaneous use as biosimilar to and interchangeable with US-licensed Prolia (denosumab) injection, 60 mg/mL in a single-dose PFS for subcutaneous use, and
- Osenvelt (denosumab-bmwo) injection, 120 mg/1.7 mL (70 mg/mL) in a single-dose vial for subcutaneous use as biosimilar to and interchangeable with US-licensed Xgeva (denosumab) injection, 120 mg/1.7 mL (70 mg/mL) in a single-dose vial for subcutaneous use.

This BLA proposes the use of Stoboclo (denosumab-bmwo) injection for:

- Treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures
- Treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
- Treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to

remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy

- Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures
- Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

This BLA proposes the use of Osenvelt (denosumab-bmwo) injection for:

- Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
- Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
- Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

For administrative purposes, we have split BLA 761404 as follows:

- BLA 761404/Original 1 – biosimilarity
- BLA 761404/Original 2 – interchangeability

The subject of this correspondence is BLA 761404/Original 2. A separate correspondence was issued for BLA 761404/Original 1.

All future submissions to these BLAs should specify the BLA number and the Original number to which each submission pertains.

We have completed a provisional review of this application, as amended. A final determination under sections 351(i) and 351(k) of the PHS Act that:

- Stoboclo (denosumab-bmwo) injection, 60 mg/mL in a single-dose PFS for subcutaneous use would be interchangeable with US-Prolia (denosumab) injection 60 mg/mL injection in a single-dose PFS for subcutaneous use, and
- Osenvelt (denosumab-bmwo) injection, 120 mg/1.7 mL in a single-dose vial for subcutaneous use would be interchangeable with US-Xgeva (denosumab) injection, 120 mg/1.7 mL in a single-dose vial for subcutaneous use,

is currently subject to unexpired exclusivity for the first interchangeable biosimilar biological products, and thus may not be made before the exclusivity has expired. See section 351(k)(6) of the PHS Act. We have not identified any deficiencies that would justify a complete response action at this time; however, we also cannot approve your application because of the unexpired first interchangeable exclusivity. We have

therefore provisionally determined that your 351(k) application meets the interchangeability criteria under section 351(k) of the PHS Act.

This provisional determination is based upon information available to the Agency at this time (i.e., information in your application and that the manufacturing of the biological product complies with the standards established in the BLA as well as the requirements in applicable regulations). This determination is subject to change on the basis of any new information that may come to our attention.

To obtain approval of this application, submit an amendment no more than six months prior to the date you believe that your application will be eligible for approval. In your cover letter, clearly identify your amendment as “**REQUEST FOR APPROVAL**”. This amendment should provide the legal/regulatory basis for your request for approval and should include a copy of any relevant supporting documentation, as appropriate. In addition to a safety update, the amendment should also identify changes, if any, in the application, i.e., updated labeling; chemistry, manufacturing, and controls data; and risk evaluation and mitigation strategy (REMS). If there are no changes, clearly state so in your cover letter. Any changes require our review before approval, and the goal date for our review will be set accordingly.

BLA 761404/Original 2 is not approved and Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) cannot be legally marketed as interchangeable biosimilar products unless and until you have been notified in writing that BLA 761404/Original 2 is approved after any necessary additional review. Enclosed are the currently agreed upon labeling (text for the Prescribing Information, Medication Guide, Carton and Container labeling). If you believe that there are grounds for issuing the approval letter before the expiration of the exclusivity period, you should amend your application accordingly.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Refer to the “Required Pediatric Assessments” section of the correspondence for BLA 761404/Original 1.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

Refer to the “Postmarketing Commitments Not Subject to the Reporting Requirements Under Section 506B” section of the correspondence for BLA 761404/Original 1.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

Section 505-1 of the Food Drug Cosmetic Act (FDCA) authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS), if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks.

Refer to the "Risk Evaluation and Mitigation Strategy Requirements" section of the correspondence for BLA 761404/Original 1.

If you have any questions, contact Noreen Cabellon, Safety Regulatory Project Manager, at 301-796-2899 or Noreen.Cabellon@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Theresa E. Kehoe, MD
Director
Division of General Endocrinology
Office of Cardiology, Hematology, Endocrinology
and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

and

{See appended electronic signature page}

Christy Osgood, MD
Supervisory Associate Director
Division of Oncology 1
Office of Oncologic Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Stoboclo Prescribing Information
 - Stoboclo Medication Guide
 - Osenvelt Prescribing Information
- Carton and Container Labeling

67 Page(s) of Draft Labeling have been Withheld in Full as B4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA E KEHOE
02/28/2025 11:33:02 AM

CHRISTY L OSGOOD
02/28/2025 11:39:07 AM